Stress, depression, and pain — but not disease activity, sleep, or physical health —  appear to be major contributors to fatigue among patients with systemic lupus erythematosus (SLE), a new study reports. The findings support that screening and treatment of these measures are included in the usual care of SLE patients, particularly…
Omalizumab — a treatment already approved for allergic asthma and chronic hives — is well-tolerated and reduces disease activity in patients with systemic lupus erythematosus (SLE), a Phase 1b clinical trial shows. Findings were published in the study, “Safety and Tolerability of Omalizumab, A Randomized Clinical…
Neovacs and Centurion Pharma will continue the joint development of the investigational vaccine IFNalpha Kinoid for people with systemic lupus erythematosus (SLE) based on the positive results of a Phase 2b clinical study. The two companies had signed a licensing agreement in July 2017, establishing a…
A diet that is higher in fiber might benefit people with autoimmune diseases like lupus by reducing the amount of disease-causing bacteria in the gut, a new study suggests. The study, “A Diet-Sensitive Commensal Lactobacillus Strain, Mediates TLR7-Dependent Systemic Autoimmunity,” was published in Cell Host & Microbe.
Rituxan (rituximab), a medicine that is often used to treat systemic lupus erythematosus (SLE), may also be effective at treating skin lesions in patients with cutaneous lupus erythematosus (CLE), a study suggests. Researchers found that one year after treatment, 61% of patients experienced improvements in their skin lesions,…
High levels of a protein called HER2 in the urine can help identify children and adolescents with lupus who are at risk of serious kidney complications, a study suggests. While the study is still ongoing, the finding suggests that the use of approved HER2 inhibitors such as Tyverb (lapatinib)…
Throughout 2018, Lupus News Today brought you coverage of important discoveries, potential disease markers, treatment developments, and clinical trials related to lupus. As we look forward to reporting more news to patients, family members, and caregivers in 2019, here are the Top 10 most-read articles of 2018. No. 10 —…
The U.S. Food and Drug Administration has granted fast track status to baricitinib for the treatment of systemic lupus erythematosus (SLE) patients, the treatment’s developers, Eli Lilly and Incyte, announced. Fast track designation is intended to speed the therapy’s development and review for lupus patients, enabling more frequent communication with…
Women who were victims of physical or emotional abuse during childhood are at a higher risk of developing systemic lupus erythematosus (SLE) later in life, a retrospective study reports. According to the findings, exposure to extreme childhood stress and adversity may…
The addition of low-dose voclosporin to standard therapy led to significantly greater remission but a higher incidence of adverse events in systemic lupus erythematosus (SLE) patients with active lupus nephritis, according to a Phase 2 clinical trial. Findings from the trial were published in the study, “…